Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have HER2-positive breast cancer that has not spread to other parts of the body (stage II or III).
- Your tumor is measurable by ultrasound or MRI.
- Your heart function, blood counts, and organ function are within normal ranges.
- You have not had any chemotherapy, radiation, or targeted therapy for this breast cancer yet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.